Hormone research in paediatrics · 2026
Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seaforth Raheem, Shafaei Niusha, Pitner Kimberly, Cho Margaret, Romero Beverly, de la Motte Anna, Brewer Kelsie, Kanakatti Shankar Roopa, Dauber Andrew
Аннотация
INTRODUCTION: Short stature resulting from genetic conditions is associated with various emotional, physical, and social challenges resulting in significantly lower health-related quality of life (HRQoL). There are minimal qualitative data available on this topic.
METHODS: We performed a cross-sectional, remote, qualitative interview study targeting children receiving vosoritide for >2 years as part of a clinical trial and their caregivers. Interviews assessed participants' daily experiences of short stature and the impact of vosoritide on HRQoL. Principles of thematic analysis were applied with features from grounded theory-guided coding and analysis of interviews.
RESULTS: Twenty-one caregivers and 14 child participants from 20 families were interviewed. Child participants were of ages 8-15 years (M = 10.2). Four conditions were represented in the sample (12 hypochondroplasia, 4 NPR2 mutations, 2 ACAN mutations, 2 Noonan syndrome). At baseline, short stature had significant impacts on physical, social, and daily activity domains. After starting vosoritide, changes were most reported for impacts on daily activities by both caregiver (74%) and child (100%) participants. Most reported were "improved ability to reach things" (12 caregivers and 14 children) and "being more independent/needing less assistance" (9 caregivers and 5 children).
CONCLUSION: Genetic short stature significantly impacts HRQoL, as reported by both children and their caregivers. Both children and caregivers noted emotional, physical, and social impacts as well as impacts on daily activities. Vosoritide treatment was associated with meaningful improvements in physical impacts and impacts on daily activities.
METHODS: We performed a cross-sectional, remote, qualitative interview study targeting children receiving vosoritide for >2 years as part of a clinical trial and their caregivers. Interviews assessed participants' daily experiences of short stature and the impact of vosoritide on HRQoL. Principles of thematic analysis were applied with features from grounded theory-guided coding and analysis of interviews.
RESULTS: Twenty-one caregivers and 14 child participants from 20 families were interviewed. Child participants were of ages 8-15 years (M = 10.2). Four conditions were represented in the sample (12 hypochondroplasia, 4 NPR2 mutations, 2 ACAN mutations, 2 Noonan syndrome). At baseline, short stature had significant impacts on physical, social, and daily activity domains. After starting vosoritide, changes were most reported for impacts on daily activities by both caregiver (74%) and child (100%) participants. Most reported were "improved ability to reach things" (12 caregivers and 14 children) and "being more independent/needing less assistance" (9 caregivers and 5 children).
CONCLUSION: Genetic short stature significantly impacts HRQoL, as reported by both children and their caregivers. Both children and caregivers noted emotional, physical, and social impacts as well as impacts on daily activities. Vosoritide treatment was associated with meaningful improvements in physical impacts and impacts on daily activities.